PDF) Idarucizumab: The antidote for reversal of dabigatran
Buy Idarucizumab Biosimilar - Anti-dabigatran etexilate mesylate mAb - Research Grade Online
The Renal Elimination Pathways of the Dabigatran Reversal Agent Idarucizumab and its Impact on Dabigatran Elimination. - Abstract - Europe PMC
Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study. - Abstract - Europe PMC
Idarucizumab for Dabigatran Reversal | NEJM
The addition of idarucizumab to plasma samples containing dabigatran allows the use of routine coagulation assays for the diagnosis of hemostasis disorders - Jacquemin - 2015 - Journal of Thrombosis and Haemostasis - Wiley Online Library
PDF) Idarucizumab: The antidote for reversal of dabigatran
Behandeling van diepe veneuze trombose in het tijdperk van de directe orale anticoagulantia | Tijdschrift voor Cardiologie
Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial - The Lancet
The addition of idarucizumab to plasma samples containing dabigatran allows the use of routine coagulation assays for the diagnosis of hemostasis disorders - Jacquemin - 2015 - Journal of Thrombosis and Haemostasis - Wiley Online Library
Idarucizumab for Dabigatran Reversal — Full Cohort Analysis | NEJM
Praxbind (idarucizumab) productbeschrijving. Het specifieke antidotum voor Pradaxa (dabigatran) 1,2 - PDF Free Download
The Renal Elimination Pathways of the Dabigatran Reversal Agent Idarucizumab and its Impact on Dabigatran Elimination. - Abstract - Europe PMC
Idarucizumab for Dabigatran Reversal — Full Cohort Analysis | NEJM
Idarucizumab for Dabigatran Reversal | NEJM
RE-VERSE AD: Idarucizumab for Dabigatran Reversal | tctmd.com
Idarucizumab for Dabigatran Reversal — Full Cohort Analysis | NEJM
Monitoring van dabigatran - PDF Free Download
Idarucizumab for Dabigatran Reversal — Full Cohort Analysis | NEJM
Idarucizumab: First Global Approval | SpringerLink
Idarucizumab for the reversal of dabigatran in patients undergoing heart transplantation - Van Keer - 2019 - European Journal of Heart Failure - Wiley Online Library
Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial - The Lancet
The Renal Elimination Pathways of the Dabigatran Reversal Agent Idarucizumab and its Impact on Dabigatran Elimination. - Abstract - Europe PMC
Predictors of outcome in patients with haematological malignancies admitted to critical care – topic of research paper in Health sciences. Download scholarly article PDF and read for free on CyberLeninka open science
The Renal Elimination Pathways of the Dabigatran Reversal Agent Idarucizumab and its Impact on Dabigatran Elimination. - Abstract - Europe PMC
Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial - The Lancet
PDF) The Renal Elimination Pathways of the Dabigatran Reversal Agent Idarucizumab and its Impact on Dabigatran Elimination
Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study | SpringerLink
